Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCash from Financing ActivitiesCash from Financing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

SELLAS Life Sciences (SLS) Change in Accured Expenses (2019 - 2024)

SELLAS Life Sciences (SLS) has disclosed Change in Accured Expenses for 9 consecutive years, with -$24000.0 as the latest value for Q4 2024.

  • Quarterly Change in Accured Expenses fell 102.98% to -$24000.0 in Q4 2024 from the year-ago period, while the trailing twelve-month figure was -$2.2 million through Dec 2024, down 250.72% year-over-year, with the annual reading at -$1.9 million for FY2025, 11.13% up from the prior year.
  • Change in Accured Expenses for Q4 2024 was -$24000.0 at SELLAS Life Sciences, down from $307000.0 in the prior quarter.
  • The five-year high for Change in Accured Expenses was $1.7 million in Q4 2022, with the low at -$1.4 million in Q2 2024.
  • Average Change in Accured Expenses over 5 years is $219000.0, with a median of $205500.0 recorded in 2022.
  • The sharpest move saw Change in Accured Expenses surged 2713.11% in 2022, then tumbled 631.63% in 2024.
  • Over 5 years, Change in Accured Expenses stood at -$391000.0 in 2020, then skyrocketed by 115.6% to $61000.0 in 2021, then soared by 2713.11% to $1.7 million in 2022, then plummeted by 53.03% to $806000.0 in 2023, then plummeted by 102.98% to -$24000.0 in 2024.
  • According to Business Quant data, Change in Accured Expenses over the past three periods came in at -$24000.0, $307000.0, and -$1.4 million for Q4 2024, Q3 2024, and Q2 2024 respectively.